18F-FDG PET or PET/CT in Mantle Cell Lymphoma |
| |
| Affiliation: | 1. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;2. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;3. HLA Foundation Laboratory, Kyoto, Japan;4. Central Japan Cord Blood Bank, Seto, Japan;5. Department of Hematology and Oncology, Nakagami Hospital, Okinawa, Japan;6. Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan;7. Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan;8. Division of Hematology and Oncology, Department of Medicine, Kurume University Hospital, Kurume, Japan;9. Department of Hematology, Kawasaki Medical School Hospital, Kurashiki, Japan;10. Department of Internal Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan;11. Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan;12. Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan;13. Department of Molecular Therapy, Advanced Clinical, Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan;14. Department of Hematology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan;15. Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan;16. Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan;17. Department of Hematology, Tokyo Women''s Medical University, Tokyo, Japan;18. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan;19. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan;20. Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan |
| |
| Abstract: | The aim of this systematic review was to examine published data about the potential role of Fluorine-18-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography (18F-FDG PET or PET/CT) in patients affected by mantle cell lymphoma (MCL).A comprehensive computer literature search of Scopus, PubMed/MEDLINE, and Embase databases was conducted, including articles indexed up to November, 2019; 25 studies or subsets in studies analyzing the value of 18F-FDG PET or PET/CT in patients with MCL were eligible for inclusion.From the analyses of the selected studies, the following main findings are described: (1) MCL are 18F-FDG-avid in most of cases, especially nodal lesions, but bone marrow and gastrointestinal disease localizations have low 18F-FDG avidity; (2) 18F-FDG PET/CT seems to be helpful in staging setting, showing a better diagnostic performance than conventional imaging and a positive impact on clinical stage; (3) 18F-FDG PET/CT is useful in evaluating treatment response, especially after chemotherapy and transplantation; and (4) metabolic response after therapy seems to have a prognostic role.Despite several limitations affecting this analysis, especially related to the heterogeneity of the studies included, MCL is an 18F-FDG-avid lymphoma in most of the cases, with the exception of bone marrow and gastrointestinal disease. Moreover, 18F-FDG PET/CT seems to be useful in evaluating treatment response and prognosis. |
| |
| Keywords: | NHL Non hodgkin lymphoma Nuclear medicine Positron emission tomography Review |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
